BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22886215)

  • 21. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.
    Ino K; Yoshida N; Kajiyama H; Shibata K; Yamamoto E; Kidokoro K; Takahashi N; Terauchi M; Nawa A; Nomura S; Nagasaka T; Takikawa O; Kikkawa F
    Br J Cancer; 2006 Dec; 95(11):1555-61. PubMed ID: 17117179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy.
    Harada K; Miyake H; Kusuda Y; Fujisawa M
    BJU Int; 2012 Dec; 110(11 Pt C):E1131-7. PubMed ID: 22712620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.
    Seeber A; Klinglmair G; Fritz J; Steinkohl F; Zimmer KC; Aigner F; Horninger W; Gastl G; Zelger B; Brunner A; Pichler R
    Cancer Sci; 2018 May; 109(5):1583-1591. PubMed ID: 29498788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma.
    de Jong RA; Kema IP; Boerma A; Boezen HM; van der Want JJ; Gooden MJ; Hollema H; Nijman HW
    Gynecol Oncol; 2012 Sep; 126(3):474-80. PubMed ID: 22668882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Ninomiya S; Hara T; Tsurumi H; Hoshi M; Kanemura N; Goto N; Kasahara S; Shimizu M; Ito H; Saito K; Hirose Y; Yamada T; Takahashi T; Seishima M; Takami T; Moriwaki H
    Ann Hematol; 2011 Apr; 90(4):409-16. PubMed ID: 20938662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy.
    Sejima T; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
    Urol Int; 2012; 88(3):263-70. PubMed ID: 22398398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited prognostic value of tumor necrosis in patients with renal cell carcinoma.
    Isbarn H; Patard JJ; Lughezzani G; Rioux-Leclercq N; Crépel M; Cindolo L; de la Taille A; Zini L; Villers A; Shariat SF; Bertini R; Karakiewicz PI
    Urology; 2010 Jun; 75(6):1378-84. PubMed ID: 19781745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer.
    Zhang T; Tan XL; Xu Y; Wang ZZ; Xiao CH; Liu R
    Chin Med J (Engl); 2017 Mar; 130(6):710-716. PubMed ID: 28303855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.
    Sørensen RB; Køllgaard T; Andersen RS; van den Berg JH; Svane IM; Straten Pt; Andersen MH
    Cancer Res; 2011 Mar; 71(6):2038-44. PubMed ID: 21406395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW; Petri E; Bichler KH; Feil G
    Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CXCR3 ligands promote expression of functional indoleamine 2,3-dioxygenase in basal cell carcinoma keratinocytes.
    Lo BK; Jalili RB; Zloty D; Ghahary A; Cowan B; Dutz JP; Carr N; Shapiro J; McElwee KJ
    Br J Dermatol; 2011 Nov; 165(5):1030-6. PubMed ID: 21711334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor.
    Shoji S; Tang XY; Umemura S; Itoh J; Takekoshi S; Shima M; Usui Y; Nagata Y; Uchida T; Osamura RY; Terachi T
    Eur Urol; 2009 Feb; 55(2):441-9. PubMed ID: 18395325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
    Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
    Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD70: a new tumor specific biomarker for renal cell carcinoma.
    Junker K; Hindermann W; von Eggeling F; Diegmann J; Haessler K; Schubert J
    J Urol; 2005 Jun; 173(6):2150-3. PubMed ID: 15879877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney.
    Zhan HC; Gudas LJ; Bok D; Rando R; Nanus DM; Tickoo SK
    Clin Cancer Res; 2003 Oct; 9(13):4897-905. PubMed ID: 14581364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.
    Eggener SE; Yossepowitch O; Pettus JA; Snyder ME; Motzer RJ; Russo P
    J Clin Oncol; 2006 Jul; 24(19):3101-6. PubMed ID: 16809736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma.
    Ben-Haj-Ayed A; Moussa A; Ghedira R; Gabbouj S; Miled S; Bouzid N; Tebra-Mrad S; Bouaouina N; Chouchane L; Zakhama A; Hassen E
    Immunol Lett; 2016 Jan; 169():23-32. PubMed ID: 26608400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
    Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
    BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
    Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H
    Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.